InBio Reports Derivative Trading Losses Amounting to 8.2 Billion KRW

[Asia Economy Reporter Park Jihwan] InBio announced on the 26th that it incurred a loss of 8.2 billion KRW from derivative transactions.

The company stated, "A derivative valuation loss was recognized due to the difference between the issuance price of the new stock subscription rights and the stock price caused by the stock price increase," adding, "This loss corresponds to a valuation loss based on fair value assessment and does not involve any cash outflow."